Using CTCs for pharmacogenomic analysis. (April 2016)

• Record Type: Journal Article
• Authors: Hart, Christopher D.; Galardi, Francesca; Pestrin, Marta; De Luca, Francesca; Risi, Emanuela; Di Leo, Angelo
• Is Part Of: Pharmacological research. Volume 106(2016:Apr.)
• Page Start: 92
• Page End: 100
• Publication Date: 2016-04
• Subjects: Circulating tumor cell -- Pharmacogenomics -- Liquid biopsy -- Biomarker -- Metastasis -- Tumor; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2016.02.019
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: In the era of precision medicine in oncology, pharmacogenomic assessment is a vital step in delivering personalized care. Increasing evidence points towards the importance of assessing molecular features of the advanced disease, rather than relying on the primary tumor sample, in order to appreciate the evolution of the tumor and to target relevant features. Circulating tumor cells (CTCs) represent a novel method of tumor sampling, as they offer a contemporaneous picture of the current disease state without the need for invasive needle biopsy. As they may derive from any number of metastatic sites, the potential to capture the heterogeneity of the disease is increased. Improvements in CTC capture, enrichment and isolation technology now allow sophisticated interrogation of these cells, such that pharmacogenomic assessment of CTCs is now possible, and the clinical potential is being explored. We review current and potential uses for CTCs for pharmacogenomic analysis.